bioAffinity Technologies Regains Nasdaq Compliance, Avoids Delisting After Meeting Listing Standards
bioAffinity Technologies Inc. announced that it has regained compliance with all applicable Nasdaq continued listing requirements. The company received written notice from Nasdaq confirming that its common stock and warrants will continue to trade on the Nasdaq Capital Market under the symbols BIAF and BIAFW. This follows the company's compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5550(b)(1), which mandates a minimum of $2.5 million in stockholders' equity. The company will be subject to a one-year Mandatory Panel Monitor period, during which any failure to comply with the equity rule could lead to delisting, although a hearing may be requested before any final action.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015832763) on October 15, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。